1
|
El Aboudi A, Lakssir J, Boualaoui I, Ibrahimi A, El-Sayegh H, Nouini Y. Bowen's disease revealing a penile invasive squamous cell carcinoma: Case report and review of literature. Int J Surg Case Rep 2024; 119:109662. [PMID: 38678992 PMCID: PMC11063890 DOI: 10.1016/j.ijscr.2024.109662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Revised: 04/07/2024] [Accepted: 04/19/2024] [Indexed: 05/01/2024] Open
Abstract
INTRODUCTION Bowen's disease (BD) represents an in situ squamous cell carcinoma that can progress to an invasive one without treatment. Various options for Bowen's disease have been delineated, each with its set of advantages and disadvantages. CASE PRESENTATION We report the case of a 60-year-old patient with a history of chronic smoking and a background of multiple partners and recurrent urethritis. The patient presented with a maculopapular lesion on the lateral aspect of the penis, evolving for 5 years. A biopsy confirmed the diagnosis of Bowen's disease. The patient underwent an excision of the lesion which the histology showed an infiltrating basosquamous cell carcinoma. DISCUSSION The diagnosis of Bowen's disease requires a biopsy and is based on histological examination. Only surgical treatment allows for the identification, through histological analysis of the excised specimen, of any potential invasive area that may not have been identified in the biopsy. Nonsurgical therapies are also an option with high recurrence rates. CONCLUSION Bowen's disease management requires a personalized approach, considering factors like lesion characteristics, patient-related variables and treatment efficacy. An adapted follow-up is recommended due to the recurrence risk associated with various treatments.
Collapse
Affiliation(s)
- Adam El Aboudi
- Department of Urology A, Ibn Sina Hospital, University of Rabat, Morocco.
| | - Jihad Lakssir
- Department of Urology A, Ibn Sina Hospital, University of Rabat, Morocco.
| | - Imad Boualaoui
- Department of Urology A, Ibn Sina Hospital, University of Rabat, Morocco.
| | - Ahmed Ibrahimi
- Department of Urology A, Ibn Sina Hospital, University of Rabat, Morocco.
| | - Hachem El-Sayegh
- Department of Urology A, Ibn Sina Hospital, University of Rabat, Morocco.
| | - Yassine Nouini
- Department of Urology A, Ibn Sina Hospital, University of Rabat, Morocco.
| |
Collapse
|
2
|
Zarka M, Tretarre B, Rebillard X, Murez T, Daures JP, Azria D, Serre I, Brel D, Ramay AS, Reis Borges R, Gevorgyan A, Hutin M, Marchal S, Korahanis N, Iborra F, Thuret R. [Cancers of the external genital organs of male in Hérault: Results from the Hérault tumor register (RTH) over a period of 30 years (1987-2016)]. Prog Urol 2021; 31:282-292. [PMID: 33593695 DOI: 10.1016/j.purol.2020.08.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 07/25/2020] [Accepted: 08/13/2020] [Indexed: 10/22/2022]
Abstract
AIM The objective of this study is to present the history of cancers of the external genital organs of male in Hérault using data from the Hérault tumor register (RTH) over a period of 30 years. PATIENTS AND METHODS Using the RTH database, we studied the development of testicular germ cell tumors (TGCT) and penile cancer (PC) over 30 years, from 1987 to 2016. We analyzed the incidence and mortality data for these tumors. We compared these results to French, European and global data. RESULTS In 30 years of registration we have recorded 725 cases of TGCT and 175 cases of PC. The age standardized incidence rate (ASR) of TGCT has doubled between 1987 and 2016 (4.2 per 100,000 in 1987 and 9.3 per 100,000 in 2016). It was multiplied by 2.63 in the population of patients aged 30 to 44. There is a decrease of the mortality rate with a ASR of 0.8 deaths per 100,000 in 1987, and 0.4/100 000 in 2016. The PC incidence ASR was stable between 1987 and 2016 (0.4-0.9/100,000). Mortality is stable with a ASR between 0.1 and 0.3 deaths per 100,000 between 1987 and 2016. CONCLUSION The incidence of TGCT has increased sharply in the Hérault over the past 30 years, while a decrease in mortality has been observed. The proportion of seminomas is increasing; it has gone from 53 % to 60 % in 30 years in the Hérault. The incidence and mortality of PC shows a stability in the Hérault over the past 30 years.
Collapse
Affiliation(s)
- M Zarka
- Service d'urologie et transplantation rénale, CHU Montpellier Lapeyronie, 371, avenue du Doyen Gaston-Giraud, 34090 Montpellier, France.
| | - B Tretarre
- Registre des tumeurs de l'Hérault, Montpellier, France
| | - X Rebillard
- Service d'urologie, clinique beau soleil, Montpellier, France
| | - T Murez
- Service d'urologie et transplantation rénale, CHU Montpellier, Montpellier, France
| | - J P Daures
- Clinique beau soleil, IURC, Montpellier, France
| | - D Azria
- ICM, Univ Montpellier, inserm U 1194, Montpellier, France
| | - I Serre
- Service d'anatomopathologie, CHU Montpellier, Montpellier, France
| | - D Brel
- Service d'anatomopathologie, CH Béziers, Béziers, France
| | - A S Ramay
- Laboratoire de biologie médicale Medipath, Montpellier, France
| | - R Reis Borges
- Laboratoire de biologie médicale Labosud-Ob Biologie, Montpellier, France
| | - A Gevorgyan
- Polyclinique Saint-Privat, Boujan sur Libron, France
| | - M Hutin
- Service d'urologie, clinique beau soleil, Montpellier, France
| | - S Marchal
- Clinique du parc, Castelnau-le-lez, France
| | | | - F Iborra
- Service d'urologie et transplantation rénale, CHU Montpellier, Montpellier, France
| | - R Thuret
- Service d'urologie et transplantation rénale, CHU Montpellier, Montpellier, France
| | | |
Collapse
|
3
|
Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE. Bull Cancer 2020; 107:eS16-eS21. [PMID: 32620211 DOI: 10.1016/s0007-4551(20)30282-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Background Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced oncogenesis. PD-L1 expression rate is around 60% with a strong correlation between PD-L1 in the primary tumour and metastases. The first line systemic treatment relies on platinum-based chemotherapies with a median progression free survival and overall survival around 7.5 and 16 months, respectively. Immunotherapies targeting PD-1/PD-L1 axis are effective in other squamous cell or HPV related cancers. Methods PULSE is a prospective multicenter open label single arm phase II study. Thirty-two patients will be enrolled after a radiological assessment showing a non-progressive disease after 3 to 6 cycles of a first line platinum-based polychemotherapy. Patients will receive Avelumab injections 10mg/ kg every two weeks until progression or unacceptable toxicity. The primary endpoint will be the progression free survival (PFS) according to RECIST v1.1 criteria. Secondary endpoints will include PFS according to iRECIST criteria, overall survival, quality of life, safety. Ancillary explorations will include assessing blood and tissue biomarkers for association with clinical benefit. Discussion After the first line, the prognosis remains poor with no consensus on a second line systemic treatment in locally advanced or mSCPC. PULSE trial is the first study that assess an anti PD-L1 immunotherapy in maintenance among patients with locally advanced or mSCPC. NCT NUMBER : NCT03774901.
Collapse
|
4
|
Alsadoun N, Devouassoux-Shisheboran M. [Pathological process for sentinel lymph node]. Bull Cancer 2020; 107:642-652. [PMID: 32037014 DOI: 10.1016/j.bulcan.2019.11.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Accepted: 11/21/2019] [Indexed: 12/18/2022]
Abstract
Sentinel node is defined as the first node to receive drainage from a primary tumor and seems to reflect the nodal status in the lymphatic drainage of the tumor. Sentinel node technique has modified the pathological examination of lymph nodes, with intraoperative evaluation of sentinel node, allowing immediate lymph node dissection in case of positive sentinel node, and histological ultrastratification to detect occult metastases. This is a literature review of different histological protocols of sentinel node according to different organs. Except for sentinel node in breast cancer and melanoma, intraoperative examination of sentinel node is helpful using frozen section, more sensitive than touch imprint cytology. Sentinel node should be embedded in paraffin block entirely after gross sectioning at two millimeters intervals parallel to the long axis of the node. Histological ultrastaging with serial sections can be helpful, but the number of sections and the interval between them is not codified. Three sections at 200-250 microns can identify the majority of micrometastases (<2mm and >200 microns). Systematic immunohistochemistry of sentinel node is not necessary for breast cancers, since isolated tumor cells do not modify the therapeutic strategy, but remains useful in other organs.
Collapse
Affiliation(s)
- Nadjla Alsadoun
- Centre hospitalier Lyon Sud, institut de pathologie multisite des hôpitaux de Lyon, 165, chemin du Grand Revoyet, 69310 Pierre-Bénite, France
| | - Mojgan Devouassoux-Shisheboran
- Centre hospitalier Lyon Sud, institut de pathologie multisite des hôpitaux de Lyon, 165, chemin du Grand Revoyet, 69310 Pierre-Bénite, France.
| |
Collapse
|